SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

IPCA Laboratories gains on the buzz of completing redemption of 2 formulation plants

11 Jan 2017 Evaluate

IPCA Laboratories is currently trading at Rs. 557.40, up by 23.10 points or 4.32% from its previous closing of Rs. 534.30 on the BSE.

The scrip opened at Rs. 540.35 and has touched a high and low of Rs. 575.00 and Rs. 537.00 respectively. So far 38,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 675.00 on 12-Jan-2016 and a 52 week low of Rs. 402.00 on 06-Jun-2016.

Last one week high and low of the scrip stood at Rs. 575.00 and Rs. 533.65 respectively. The current market cap of the company is Rs. 7,032.78 crore.

The promoters holding in the company stood at 46.13%, while Institutions and Non-Institutions held 37.99% and 15.88% respectively.

IPCA Laboratories has reportedly completed redemption of 2 formulation plants Pithampur and Piparia. The undergoing verification of these two plants was held by third party consultants. The verification process of these 2 plants is likely to be completed by March 2017.

IPCA Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.


Ipca Laboratories Share Price

1613.05 -21.20 (-1.30%)
11-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1275.05
Cipla 1383.00
Zydus Lifesciences 1105.65
Lupin 2274.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: